her2-positive - OmicsDI

Show results for

Unknown (5705)
Transcriptomics (3248)
Genomics (494)
Proteomics (79)
Clinical (55)
Other (16)
Methylation profiling (11)
Genomic (9)
Metabolomics (5)
Models (2)

Organisms

Homo sapiens (1629)
Mus musculus (851)
Rattus norvegicus (103)
Arabidopsis thaliana (76)
Drosophila melanogaster (54)
Saccharomyces cerevisiae (51)
Danio rerio (36)
Bos taurus (28)
Gallus gallus (28)
Sus scrofa (28)
Caenorhabditis elegans (21)
Zea mays (18)
Oryza sativa (17)
Oryza sativa Japonica Group (11)
Canis lupus familiaris (10)
Escherichia coli (10)
Macaca mulatta (9)
Schizosaccharomyces pombe (8)
Oncorhynchus mykiss (8)
Medicago truncatula (7)
Ovis aries (7)
Salmo salar (6)
Streptococcus pneumoniae D39 (6)
Colinus virginianus (5)
Staphylococcus aureus (5)
Glycine max (5)
Mycobacterium tuberculosis H37Rv (5)
Boehmeria nivea (4)
Campylobacter jejuni subsp. jejuni NCTC 11168 = ATCC 700819 (4)
Mammalia (1)

Organisms

Homo sapiens (301)
Mus musculus (24)
Homo (2)
Macaca mulatta (1)

Repository

biostudies-arrayexpress (3095)
ENA (382)
geo (263)
EGA (39)
pride (26)
MassIVE (20)
LINCS (12)
dbGaP (9)
jPOST (8)
MetaboLights (5)
PanoramaPublic (5)
ExpressionAtlas (3)
BioModels (2)
iProX (2)
EVA (1)

Tissue

Cell culture (11)
Epithelial cell (10)
Breast (5)
Breast cancer cell (3)
Liver (2)
Permanent cell line cell (2)
Blood (1)
Blood cell (1)
Blood plasma (1)
Blood serum (1)
Breast invasive ductal carcinoma cell (1)
Culture fluid (1)
Fibroblast of mammary gland (1)
T cell (1)

Disease

Breast cancer (22)
Colorectal Neoplasms (15)
Carcinoma (8)
Breast Neoplasms (6)
Neoplasms (6)
Normal (5)
Stomach Neoplasms (3)
Colorectal cancer (2)
Colorectal cancer (2)
Breast tumor luminal (1)
HER2 Positive Breast Carcinoma (1)
Triple-negative breast cancer (1)
CLL (1)
Arrhythmias and right ventricular dysfunction (1)
GIP-dependent Cushing's syndrome (1)
HPV positive (1)
Osteosarcoma subtype fibroblastic (1)
High grade glioblastoma (1)
Cocaine addiction (1)
Primary effusion lymphoma (PEL) (1)
DNA damage (1)
ER positive breast cancer (1)
Uninfected (1)
Schizophrenia (1)
Leukemia (1)
Renal cell carcinoma (1)
Glioblastoma (1)
Prostate carcinoma (1)
Adenocarcinoma (1)
Adenocarcinoma (1)

Technology Type

Mass Spectrometry (26)
Shotgun proteomics (12)
Fluorescence imaging (8)
Fluorescence intensity (8)
Bottom-up proteomics (7)
Illumina HiSeq 2000 (3)
Mass spectrometry (3)
Mass spectrometry (3)
Affinity purification coupled with mass spectrometry proteomics (3)
Top-down proteomics (3)
Data-dependent acquisition (2)
454 GS FLX Titanium, Illumina HiSeq 2000 (1)
CYTOSCANHD, ILLUMINA, HUMANOMNI1QUAD, HUMANOMNIEXPRESS, Affymetrix HG_U133_+2, Illumina HiSeq 2000 (1)
ILLUMINA, Illumina Genome Analyzer II, Illumina HiSeq 2000 (1)
Illumina Genome Analyzer II, Illumina HiSeq 2000 (1)
Illumina HiSeq 2500 (1)
Illumina HiSeq 2500, Illumina HiSeq 4000, ILLUMINA, NextSeq 500 (1)
Illumina MiSeq (1)
DNA sequencing (1)
RNA-seq (1)
Mass spectrometry assay (1)
NMR spectroscopy (1)
Gel-based experiment (1)
SRM/MRM (1)
SWATH MS (1)

Instrument Platform

NextSeq 500 (7)
Q Exactive (7)
Illumina HiSeq 2500 (6)
Illumina NovaSeq 6000 (6)
Illumina HiSeq 2000 (5)
Orbitrap Fusion Lumos (5)
Illumina HiSeq 4000 (3)
Illumina Genome Analyzer II (2)
Illumina MiSeq (2)
Orbitrap Exploris 480 (2)
Liquid Chromatography MS - negative - reverse phase (2)
Liquid Chromatography MS - positive - reverse phase (2)
Agilent 2100 Bioanalyzer, Applied Biosystems 7900HT Sequence Detection System, Illumina TruSeq Small RNA Sample Preparation Kit (1)
RNeasy mini Kit, Ribo-Zero Human/Mouse/Rat kit (1)
Solexa 2G Genome Analyzer (1)
Agilent 2100 Bioanalyzer (1)
Agilent Technologies Scanner G2505C (1)
MinION (1)
NextSeq 550 (1)
6560 Q-TOF LC/MS (1)
LTQ (1)
NanoACQUITY UPLC (1)
Orbitrap Eclipse (1)
Orbitrap Fusion (1)
Q Exactive HF (1)
Q Exactive Plus (1)
Synapt G2 HDMS (1)
Synapt G2-S MS (1)
Bruker (1)
Liquid Chromatography MS - negative - HILIC (1)

Publication Date

2015 (590)
2010 (519)
2013 (439)
2011 (345)
2014 (339)
2012 (332)
2016 (162)
2009 (144)
2008 (137)
2007 (78)
2025 (45)
2024 (40)
2022 (37)
2026 (35)
2021 (29)
2023 (28)
2006 (27)
2020 (26)
2018 (26)
2019 (20)
2017 (15)
2005 (14)
2004 (7)
2003 (6)
2002 (1)

UNIPROT ID/AC

P01133 (1)
P04049 (1)
P08646 (1)
P17252 (1)
P30086 (1)
P31749 (1)
P61981 (1)
P62714 (1)
Q02750 (1)
Q504U8 (1)

CHEBI ID

CHEBI:114785 (1)
CHEBI:15996 (1)
CHEBI:17552 (1)
CHEBI:108517|CHEBI:108532 (1)
CHEBI:108633 (1)
CHEBI:108918 (1)
CHEBI:109146|CHEBI:109455 (1)
CHEBI:109896 (1)
CHEBI:127309 (1)
CHEBI:131458 (1)
CHEBI:131459 (1)
CHEBI:131460 (1)
CHEBI:131478 (1)
CHEBI:131976 (1)
CHEBI:131977 (1)
CHEBI:132770 (1)
CHEBI:132807 (1)
CHEBI:15354 (1)
CHEBI:15366 (1)
CHEBI:15428 (1)
CHEBI:15603 (1)
CHEBI:15971 (1)
CHEBI:16015 (1)
CHEBI:16024 (1)
CHEBI:16414 (1)
CHEBI:16643 (1)
CHEBI:16737 (1)
CHEBI:16919 (1)
CHEBI:16977 (1)
CHEBI:17066 (1)

Metabolite Name

(R)-3-hydroxybutyrate (1)
(S)-lactic acid (1)
Cer(d18:1/17:0) (1)
Cer(d18:1/22:6) (1)
Custom adduct of 794,726 m/z - TG(46:1) (1)
Custom adduct of 796,742 m/z - TG(14:0/16:0/16:0)+TG(16:0/18:0/12:0) (1)
Custom adduct of 818,728 m/z - TG(48:3) (1)
Custom adduct of 820,742 m/z - TG(48:2) (1)
Custom adduct of 834,759 m/z - TG(49:2) (1)
Custom adduct of 836,774 m/z - TG(49:1) (1)
D-glucose (1)
D-mannose (1)
L-alanine (1)
L-glutamic acid (1)
L-glutamine (1)
L-histidine (1)
L-isoleucine (1)
L-leucine (1)
L-methionine (1)
L-phenylalanine (1)
L-proline (1)
L-tyrosine (1)
L-valine (1)
LysoPC(14:0) (1)
LysoPC(16:0e) (1)
LysoPC(16:1) (1)
LysoPC(18:0) (1)
LysoPC(18:1) (1)
LysoPC(18:2) (1)
LysoPC(18:3) (1)

First Public Date

2014 (59)
2025 (52)
2024 (50)
2026 (41)
2023 (28)
2020 (27)
2021 (25)
2022 (24)
2015 (21)
2017 (17)
2018 (16)
2019 (10)
2016 (7)
2013 (5)

Modelling Approach

Ordinary differential equation model (2)

Study status

Recruiting (16)
Completed (10)
Active, not recruiting (7)
Not provided (6)
Not yet recruiting (6)
Terminated (4)
Withdrawn (3)
Available (1)
Ongoing (1)
Suspended (1)

Lab affiliation

Baylor College of Medicine (1)
Biological Engineering, MIT (1)
Cancer Biomarkers Research Group Health Research Institute-Fundacion Jimenez Diaz (IIS-FJD, UAM) Madrid, Spain (1)
Cancer Science Institute of Singapore (CSI), National University of Singapore (NUS) (1)
Central Laboratory, Wuxi Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University (1)
Centre for Genomics and Computational Biology Barts Cancer Institute Queen Mary, University of London John Vane Science Centre, Charterhouse Square, London EC1M 6BQ Tel: +44 (0)20 7882 8266 (1)
Department of Human Molecular Genetics and Biochemistry Sackler Faculty of Medicine, Tel Aviv University Israel (1)
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (1)
Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA (1)
Department of Neurology, Laboratory of Neuro‑Oncology, Clinical and Cancer Proteomics, Erasmus University Medical Center (1)
Department of Nuclear Medicine and Radiobiology Faculty of Medicine and Health Sciences Université de Sherbrooke Sherbrooke, Quebec, Canada (1)
Department of Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS—FJD, UAM)—CIBERONC, Madrid 28040, Spain. (1)
Department of Pharmacology, University of North Carolina Chapel Hill School of Medicine, Chapel Hill, NC USA (1)
Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA (1)
Gladstone Institutes, San Francisco, CA, USA Quantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, CA, USA Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA (1)
Instituto de Investigaciones Sanitarias de Santiago de Compostela (1)
Laboratory Medicine and Pathology Mayo Clinic USA (1)
Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Strasse 10, 13125 Berlin, Germany Department of Chemistry, Humboldt Universität zu Berlin, Brook-Taylor-Straße 2, 12489 Berlin, Germany (1)
MRC Protein Phosphorylation Unit, University of Dundee, Dundee, United Kingdom (1)
Maria Skłodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland (1)
Mass Spectrometry Facility Barts Cancer Institute, Queen Mary,University of LondonRoom 1.02-1.03, 1st Floor, John Vane Science Centre Charterhouse Square London EC1M 6BQ (1)
Nanjing Drum Tower Hospital (1)
Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS—FJD, UAM), Madrid 28040, Spain (1)
Principal Investigator Universidade de Coimbra • Faculdade de Medicina | University of Coimbra • Faculty of Medicine Instituto de Investigação Clínica e Biomédica de Coimbra (iCBR) | Coimbra Institute for Clinical and Biomedical Research (iCBR) (1)
Professor Research Institute-MUHC Cancer Research Program,Montreal (1)
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry (1)

Keyword

Trastuzumab (17)
HER2 (12)
Immunotherapy (8)
Tucatinib (7)
Cetuximab (4)
Leucovorin (4)
Pembrolizumab (4)
Seattle Genetics (4)
Tislelizumab (4)
Bevacizumab (3)
Capecitabine (3)
Cyclophosphamide (3)
ERBB2 (3)
Fluorouracil (3)
HER2+ (3)
Levoleucovorin (3)
Oxaliplatin (3)
Ado-Trastuzumab Emtansine (2)
Advanced Colorectal Cancer (2)
Aldesleukin (2)
Biliary tract cancer (2)
Breast (2)
CRC (2)
Cell therapy (2)
Colorectal (2)
Disitamab vedotin (2)
EGFR (2)
EGFR Positive (2)
EGFR+ (2)
Fludarabine (2)

IsPrivate

False (2)

Study type

Transcription profiling by array (2268)
RNA-seq of coding RNA (385)
Unknown experiment type (100)
RNA-seq of non coding RNA (77)
Comparative genomic hybridization by array (42)
Other (40)
Transcription profiling by SAGE (30)
ChIP-chip by tiling array (28)
Methylation profiling by array (28)
ChIP-seq (26)
Proteomic profiling by array (15)
Transcription profiling by RT-PCR (14)
Transcription profiling by tiling array (12)
Genotyping by array (6)
Methylation profiling by high throughput sequencing (6)
High-throughput sequencing (2)
ChIP-chip by array (2)
MicroRNA profiling by high throughput sequencing (2)
ChIP-chip by SNP array (1)
Transcription profiling by MPSS (1)
Differential (1)
Human - One-color microarray (1)
Animal - High-throughput sequencing (1)
Proteomic profiling by mass spectrometer (1)
RNAi profiling by array (1)
Bisulfite-seq (1)
MicroRNA profiling by array (1)
DNA-seq (1)
Genotyping by high throughput sequencing (1)
RNA-seq of total RNA (1)

Release Date

2015 (755)
2025 (727)
2023 (721)
2022 (676)
2021 (631)
2024 (598)
2010 (535)
2013 (526)
2014 (495)
2020 (454)
2016 (440)
2012 (404)
2011 (386)
2019 (333)
2018 (305)
2017 (270)
2009 (160)
2008 (144)
2026 (88)
2007 (84)
2006 (29)
2005 (14)
2004 (9)
2003 (6)
2002 (2)

Location

United States (25)
China (14)
Japan (8)
Spain (8)
United Kingdom (8)
Italy (7)
South Korea (7)
Belgium (5)
Canada (5)
Australia (4)
Germany (3)
Poland (3)
Austria (2)
France (2)
Ireland (2)
Israel (2)
Netherlands (2)
Taiwan (2)
Argentina (1)
Brazil (1)
Chile (1)
Czechia (1)
Greece (1)
Hungary (1)
Norway (1)
Portugal (1)
Russia (1)
Slovakia (1)
South Africa (1)
Switzerland (1)

Previous page
1 / 963
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 963
Next page

Sort by:

Relevance

Page size

mRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer

The intention was to detect genes that are determining trastuzumab efficiency in HER2-positive breast cancer cell lines with different resistance phenotypes. While BT474 should be sensitive to the drug treatment, HCC1954 is expected to be resistant due to a PI3K mutation. The cell line BTR50 has bee...

ORGANISM(S): Homo sapiens

2015-04-21 | E-GEOD-55005 | biostudies-arrayexpress

An Integrated Model of the Transcriptome Landscape of HER2-Positive Breast Cancer

The goal of our study is to build an integrated transcriptome landscape model for HER2 positive breast tumors and identify the crucial signaling pathways associated with HER2 tumors. Genomic features include, 685 genes that were differentially expressed only in HER2-positive tumors, 102 genes that w...

ORGANISM(S): Homo sapiens

2013-12-06 | E-GEOD-45419 | biostudies-arrayexpress

Identification of strategies to overcome resistance in HER2 positive breast cancer.

The use of trastuzumab and pertuzumab in combination with docetaxel for initial treatment of HER2-positive breast cancer patients has resulted in notable clinical benefits in comparison to docetaxel administered with trastuzumab alone. Nevertheless, although therapeutic success is evident at the out...

ORGANISM(S): Homo sapiens (Human)

2024-01-26 | PXD045804 | Pride

Nuclear factor kappa B activation-induced anti-apoptosis renders HER2 positive cells drug resistant and accelerates tumor growth

Breast cancers with HER2 overexpression are sensitive to drugs targeting the receptor or its kinase activity. HER2-targeting drugs are initially effective against HER2- positive breast cancer, but resistance inevitably occurs. We previously found that nuclear factor kappa B is hyper-activated in the...

ORGANISM(S): Homo sapiens

2014-02-13 | E-GEOD-52707 | biostudies-arrayexpress

Characterization and therapeutic repercussion of the ecology in HER2 positive breast cancer

Conditioned medium experiments carried out in our laboratory with CAFs derived from HER2-positive patients showed a significant capacity to promote resistance to trastuzumab plus pertuzumab therapies in two HER2-positive breast cancer cell lines (BCCLs), even in the presence of docetaxel. In order t...

ORGANISM(S): Homo sapiens (Human)

2022-01-26 | PXD025556 | Pride

Breast cancer her2-positive tumour microenvironment targeted-therapy trastuzumab resistance cancer-associated fibroblast label-free proteomics

caArray_harri-00137: Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer

To assess pathologic complete response (pCR), clinical response, feasibility, safety, and potential predictors of response to preoperative trastuzumab plus vinorelbine in patients with operable, human epidermal growth factor receptor 2 (HER2)-positive breast cancer. EXPERIMENTAL DESIGN: 48 patients ...

ORGANISM(S): Homo sapiens

2015-06-25 | E-GEOD-70233 | biostudies-arrayexpress

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

HER2 targeting with trastuzumab has changed the prognosis of breast cancer patients carrying amplification and/or overexpression of this oncogene. Despite this progress, however, resistance to trastuzumab occurs in the vast majority of patients. Newer anti-HER2 therapies, like the dual tyrosine-kina...

ORGANISM(S): Homo sapiens

2010-12-15 | E-GEOD-17630 | biostudies-arrayexpress

Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer.

Not available

S-EPMC8508505 | biostudies-literature

MUC1 triggers lineage plasticity of Her2 positive mammary tumor

PRJNA814266 | ENA

Genome-wide DNA methylation analysis of HER2-positive breast cancer and stroma

PRJNA737795 | ENA

Previous page
1 / 963
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 963
Next page

Sort by:

Relevance

Page size

9624 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

UNIPROT ID/AC

CHEBI ID

Metabolite Name

First Public Date

Modelling Approach

Study status

Lab affiliation

Tags

Keyword

IsPrivate

Study type

Release Date

Location

OmicsDI is part of the ELIXIR infrastructure

Tweets